COPS3在肝癌中的表達_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 唐彪 ,  段群歡

永州市中心醫院肝膽外科（湖南永州 425000）;

Corresponding?author：

段群歡, Email: duanqunhuan900@163.com

Keywords：

DOI：

10.7507/1007-9424.20150391

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的研究構成型光形態建成同源亞基3（COPS3）在肝癌中的表達。方法應用免疫組織化學SP法及RT-PCR法檢測肝癌組織中COPS3表達情況。結果肝癌組織中COPS3蛋白表達陽性率〔46.7%（14/30）〕明顯高于正常肝臟組織〔23.3%（7/30），χ²=5.654，P=0.017〕及肝硬變組織〔36.7%（11/30），χ²=4.979，P=0.026〕，差異具有統計學意義。肝癌組織中COPS3 mRNA的轉錄水平亦明顯高于肝硬變及正常肝臟組織，差異具有統計學意義（P＜0.05）；在肝癌組織中，COPS3在細胞核中的表達陽性率明顯高于在細胞漿中的表達陽性率（χ²=6.674，P=0.009）。結論 COPS3在肝癌組織中表達水平和定位均發生改變，可能參與了肝癌的發生和發展過程。

Citation： 唐彪, 段群歡. COPS3在肝癌中的表達. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(12): 1507-1509. doi: 10.7507/1007-9424.20150391 Copy

1.	Greten TF, Korangy F, Manns MP, et al. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer, 2009, 100(1): 19-23.
2.	Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.
3.	Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29(36): 4989-5005.
4.	Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21(6): 607-612.
5.	Kato JY, Yoneda-Kato N. Mammalian COP9 signalosome. Genes Cells, 2009, 14(11): 1209-1225.
6.	Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest, 2011, 121(3): 851-865.
7.	Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget, 2011, 2(3): 234-238.
8.	Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 2010, 24(15): 1580-1589.
9.	Yan T, Tang G, Ren T, et al. RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther, 2011, 18(6): 450-456.
10.	Henriksen J, Aagesen TH, Maelandsmo GM, et al. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene, 2003, 22(34): 5358-5361.
11.	Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.

1. Greten TF, Korangy F, Manns MP, et al. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer, 2009, 100(1): 19-23.
2. Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.
3. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29(36): 4989-5005.
4. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21(6): 607-612.
5. Kato JY, Yoneda-Kato N. Mammalian COP9 signalosome. Genes Cells, 2009, 14(11): 1209-1225.
6. Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest, 2011, 121(3): 851-865.
7. Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget, 2011, 2(3): 234-238.
8. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 2010, 24(15): 1580-1589.
9. Yan T, Tang G, Ren T, et al. RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther, 2011, 18(6): 450-456.
10. Henriksen J, Aagesen TH, Maelandsmo GM, et al. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene, 2003, 22(34): 5358-5361.
11. Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.

Previous Article
Fever as Initial Symptom of Intrahepatic Cholangiocellular Carcinoma: Report of 4 Cases
Next Article
乳房Paget病16例臨床分析

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

COPS3在肝癌中的表達

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content